Jessica Tullis
Nurse Practitioner · Fort Wayne, INNPI 1568951887
Payments from drug & device makers
Across 306 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$756
- Novo Nordisk$599
- Pfizer$575
- Axsome Therapeutics, Inc.$423
- AstraZeneca$361
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,841100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $1,251 |
| Lilly USA, LLC | 29 | $756 |
| Novo Nordisk | 28 | $599 |
| Pfizer | 24 | $575 |
| Axsome Therapeutics, Inc. | 12 | $423 |
| AstraZeneca | 17 | $361 |
| Otsuka America Pharmaceutical, Inc. | 10 | $279 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $186 |
| GSK | 6 | $166 |
| Bayer | 8 | $165 |
| Boehringer Ingelheim | 9 | $155 |
| Lundbeck LLC | 7 | $147 |
| Amgen | 9 | $137 |
| Xeris Pharmaceuticals, Inc. | 7 | $123 |
| Astellas Pharma US Inc | 5 | $122 |
| Phathom Pharmaceuticals, Inc. | 2 | $113 |
| Medtronic | 2 | $110 |
| Abbott | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 5 | $104 |
| Therapeuticsmd, Inc. | 1 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $97 |
| Sunovion Pharmaceuticals Inc. | 4 | $95 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Merck | 5 | $81 |
| Corium, LLC | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $77 |
| Exact Sciences | 4 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Ironwood Pharmaceuticals, Inc | 2 | $38 |
| Eisai Inc. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Insulet Corporation | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,861 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $30,020 |
| MounjaroTirzepatide | 14 | $14,817 |
| EliquisApixaban | 11 | $13,734 |
| Spiriva RespimatTiotropium Bromide | 23 | $13,235 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,776 |
| LumiganBimatoprost | 13 | $3,562 |
| Brimonidine Tartrate | 17 | $2,661 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $2,556 |
| PremarinEstrogens, Conjugated | 12 | $2,424 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,767 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $1,108 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 14 | $977 |
| Famotidine | 74 | $874 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $873 |
| Levothyroxine Sodium | 109 | $842 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $166 | $35,79648 claims |
| PfizerEliquis, Premarin | $575 | $16,15823 claims |
| Lilly USA, LLCMounjaro | $756 | $14,81714 claims |
| Boehringer IngelheimSpiriva Respimat | $155 | $13,23523 claims |
| AbbVieLumigan, Synthroid | $1,251 | $4,38332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Fort Wayne
- Sean GoddardFort Wayne$180K
- Kristine TaylorFort Wayne$69K
- Mary BullisFort Wayne$27K
- Nathan MinerFort Wayne$21K
- Joel NagelFort Wayne$20K
- Gabriela NorthFort Wayne$18K
- Karen LothamerFort Wayne$12K
- Pamela ShodaFort Wayne$11K
- Sara CoburnFort Wayne$9K
- Marlise FletterFort Wayne$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.